CJC-1295 with DAC (Long-Acting GHRH Analog)

CJC-1295 with DAC is an experimental synthetic peptide classified as a GHRH (Growth Hormone-Releasing Hormone) analog, primarily investigated for its effects on pituitary growth hormone secretion and related endocrine signaling pathways.

A key structural feature of CJC-1295 is the incorporation of a Drug Affinity Complex (DAC). This modification is designed to promote prolonged association with circulating albumin, extending the compound’s pharmacokinetic profile and duration of biological activity compared with shorter-acting GHRH-related peptides.

In endocrine research, CJC-1295 with DAC is studied in connection with GHRH receptor activation, pituitary GH secretion, the GH/IGF-1 axis, pulsatile growth hormone signaling, and associated metabolic and endocrine regulatory mechanisms.

It can also serve as a research tool for comparing long-acting GHRH analogs with native GHRH and related research peptides in terms of signaling duration, receptor activity, and endocrine responses.

CJC-1295 with DAC remains an investigational compound and is not an approved treatment for muscle enhancement, fat loss, anti-aging, or athletic performance. Experimental findings should therefore not be interpreted as established human benefits.

Livraison standard offerte dès 50 $ vers les États-Unis, le Canada, le Mexique et l'Europe. Expédition sous 1 jour ouvré.

Pas convaincu ? Renvoyez le produit sous 30 jours pour un remboursement intégral, même ouvert.